<DOC>
	<DOCNO>NCT00397488</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzyme need growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient progressive metastatic transitional cell cancer urothelium .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Progressive Metastatic Transitional Cell Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient progressive metastatic transitional cell carcinoma urothelium treat sunitinib malate . - Determine safety regimen patient . Secondary - Determine time disease progression patient treat regimen . - To determine time tumor progression ( TTP ) sunitinib malate continuous dose schedule treatment metastatic urothelial carcinoma . - To estimate sunitinib SU012662 trough plasma concentration ( Ctrough ) data continuous daily schedule determine potential association efficacy safety .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium , include 1 follow site : Bladder Urethra Ureter Renal pelvis Progressive metastatic disease Progressive disease define new progressive lesion crosssectional imaging Progressed despite prior treatment cytotoxic chemotherapy Measurable disease Previously treat disease , define following : Received treatment 14 cytotoxic agent Prior therapy must include ≥ 1 following : Cisplatin Carboplatin Paclitaxel Docetaxel Gemcitabine hydrochloride Prior cytotoxic agent perioperative metastatic setting allow may administer sequentially ( e.g. , firstline treatment follow secondline treatment time progression ) part single regimen No symptomatic CNS metastases PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL Bilirubin ≤ 1.5 mg/dL ( unless Gilbert 's disease present ) AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver function abnormality due underlying malignancy ) Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception None follow within past 6 month : Myocardial infarction Severe unstable angina Coronary peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism No ongoing cardiac dysrhythmias ≥ grade 2 No prolong QTc interval baseline ECG No uncontrolled hypertension , define blood pressure &gt; 150/100 mm Hg despite optimal medical therapy No preexisting thyroid abnormality ( i.e. , thyroid function test maintain normal range medication ) No know HIV AIDSrelated illness active infection PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior radiotherapy chemotherapy At least 4 week since prior major surgery No concurrent investigational drug No concurrent participation another clinical trial ( supportive care trial nontreatment trial [ e.g. , quality life ] allow ) No concurrent therapeutic dos warfarin ( lowdose warfarin ≤ 2 mg daily thromboembolic prophylaxis allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>